• 1
    Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994: 272: 20511.
  • 2
    Anonymous. Trends in ischemic heart disease deaths—United States, 1990–1994. MMWR. 1997;46: 14650.
  • 3
    Björvell H., Rössner S. Short communication: a ten-year fol low-up of weight change in severely obese subjects treated in a combined behavioural modification programme. Int J Obes. 1992; 16: 6235.
  • 4
    Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222: 33950.
  • 5
    Sjostrom CD, Lissner L., Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS intervention Study. Obes Res 1997 5 51930.
  • 6
    Atkinson RL, Blank RC, Schumacher D., Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res. 1997;5: 57886.
  • 7
    Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995: 75: 47386.
  • 8
    Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Eng J Med. 1997;337: 5818.
  • 9
    Edelstein, EG, ed. 96 First Blue Book Databank. New York, NY: Hearst Corporation; 1995.
  • 10
    Hunninghake DB. Hyperlipoproteinemias. In: Rakel R., ed. Conn's Current Therapy. Philadelphia, PA: W. B. Saunders Company; 1997;5615.
  • 11
    Gordon DJ, Rifkind BM. High-density lipoprotein—the clinical implications of recent studies. N Eng J Med. 1989; 321: 13116.
  • 12
    Appel LJ, Moore TJ, Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336: 111724.
  • 13
    Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profiles. AHA Medical/Scientific Statement 1991;83: 35662.
  • 14
    Kreisberg RA. Hyperlipidemia. In: Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. St. Louis, MO: Mosby Publishing; 1997;50919.
  • 15
    NIH Consensus Development Conference Statement. Health implications of obesity. Ann Intern Med. 1985; 103: 19737.
  • 16
    Weintraub M., Sundaresan PR, Schuster B., et al. Long term weight control: the National Heart, Lung and Blood Institute funded multimodal intervention study. I-VII. Clin Pharmacol Ther. 51: 581446.
  • 17
    Petzoldt R., Oeynhausen B. Cost reduction in drug therapy of diabetes (German). Versicherungsmedizin. 1989;41: 747.
  • 18
    Collins RW, Anderson JW. Medication cost savings associ ated with weight loss for obese non-insulin-dependent diabetic men and women. Prev Med. 1995;24: 36974.
  • 19
    Munro JF, MacCuish AC, Wilson EM, Duncan LJP. Com parison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1: 3526.
  • 20
    Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner. 1981;225: 2312.
  • 21
    Schteingart DE. Effectiveness of phenylpropanolamine in the management of moderate obesity. Int J Obes. 1992; 16: 48793.
  • 22
    Lean ME. Sibutramine—a review of clinical efficacy. Int J Obes. 1977;1: S306.
  • 23
    Bray GA, Ryan DH, Gordon D., Heidingsfelder S., Cerise F., Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4: 26370.
  • 24
    Ryan DH, Kaiser P., Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res. 1995;4: 553898.
  • 25
    Inoue S. Clinical studies with mazindol. Obes Res. 1995; 3: S54952.
  • 26
    Astrup A., Breum L., Toubro S., Hein P., Quaade F. The effect and safety of an ephedrinekaffeine compound com pared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes. 1992: 16: 26977.
  • 27
    Toubro S., Astrup A., Breum L., Quaade F. The acute and chronic effects of ephedrinekaffeine mixtures on energy ex penditure and glucose metabolism in humans. Int J Obes. 1993;3: S737.
  • 28
    Greenway FL. Obesity. In: Rakel R., ed. Conn's Current Therapy. Philadelphia, PA: W. B. Saunders Company; 1997;56472.
  • 29
    Astrup A., Breum L., Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res. 1995;4: 537S40S.
  • 30
    Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res. 1998;6: 97106.
  • 31
    Herman WH, Dasbach EJ, Songer TJ, Eastman RC. The cost-effectiveness of intensive therapy for diabetes mellitus. Endocrinol Metab Clin North Am. 1997;26: 67995.